Bin S. Teh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bin S. Teh has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
Arnold C. Paulino
The Methodist Hospital, Cancer Center and Research Institute
10 shared publicationsE. Brian Butler
Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute
10 shared publicationsHiromichi Ishiyama
Kitasato University School of Medicine
9 shared publications- E. Brian Butler
Houston Methodist Hospital, Houston, TX
8 shared publications - Simon S. Lo
University of Washington
8 shared publications Angel I. Blanco
Department of Radiation Oncology, Houston Methodist Hospital, Cancer Center and Research Institute
7 shared publications
Latest Publications
- 10 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (5_suppl) , 112
Risk for pulmonary late effects in childhood Hodgkin lymphoma survivors.
112 Background: Survivors of Hodgkin lymphoma (HL) are at risk for pulmonary late effects, including pulmonary fibrosis (PF). Established risk factors such as younger age at diagnosis and specific therapeutic exposures explain a fraction of the risk for these outcomes. Notably, systemic inflammation and impaired telomere maintenance are associated with adverse pulmonary outcomes in adult populations, but have not been explored in cancer survivors. Our aim was to identify pulmonary diffusion defects in HL survivors, and evaluate the impact of short lymphocyte telomere length (LTL) and systemic inflammation on these outcomes. Methods: Blood samples, demographic and treatment data, and lung carbon monoxide diffusion capacity corrected for hemoglobin and alveolar volume (DLCO) were obtained from HL survivors ≥6 months off therapy and without history of relapse or transplant. LTL was measured by telomere flow FISH (Repeat Diagnostics), and age-based percentiles determined from population controls. Plasma elevations in pro-inflammatory cytokines (HCYTMAG panel, EMD Millipore) were detected on a Luminex platform. Associations between clinical features and most recent DLCO were determined by linear regression, adjusted for age, sex, radiation, and race/ethnicity. In a subset of subjects, cytokine levels and LTL were compared in survivors with DLCO above or below the mean using a Student t-test or Fisher’s Exact test, respectively. Results: Seventy-two HL survivors met inclusion criteria (mean age at diagnosis=14 years, range: 3-18 years). Mean off-therapy DLCO was 75% (range: 52-98%), below the lower limit of normal (76%) in healthy populations. DLCO was inversely associated with female sex (p = 0.002). Five of 24 survivors (21%) had LTL ≤10th percentile for age, but there was no difference in LTL relative to DLCO. Survivors with DLCO ≤75% had higher IL1α and IL1β levels (n = 30, p = 0.07). Conclusions: HL survivors had lower than expected DLCO, with females at highest risk for impaired pulmonary diffusion. Twice as many survivors as expected had LTL ≤10th percentile, and PF-related cytokine profiles were observed in survivors with lower DLCO, suggesting inflammation and telomere maintenance defects may contribute to late effects in HL survivors.
- 10 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (5_suppl) , 112
Risk for pulmonary late effects in childhood Hodgkin lymphoma survivors.
112 Background: Survivors of Hodgkin lymphoma (HL) are at risk for pulmonary late effects, including pulmonary fibrosis (PF). Established risk factors such as younger age at diagnosis and specific therapeutic exposures explain a fraction of the risk for these outcomes. Notably, systemic inflammation and impaired telomere maintenance are associated with adverse pulmonary outcomes in adult populations, but have not been explored in cancer survivors. Our aim was to identify pulmonary diffusion defects in HL survivors, and evaluate the impact of short lymphocyte telomere length (LTL) and systemic inflammation on these outcomes. Methods: Blood samples, demographic and treatment data, and lung carbon monoxide diffusion capacity corrected for hemoglobin and alveolar volume (DLCO) were obtained from HL survivors ≥6 months off therapy and without history of relapse or transplant. LTL was measured by telomere flow FISH (Repeat Diagnostics), and age-based percentiles determined from population controls. Plasma elevations in pro-inflammatory cytokines (HCYTMAG panel, EMD Millipore) were detected on a Luminex platform. Associations between clinical features and most recent DLCO were determined by linear regression, adjusted for age, sex, radiation, and race/ethnicity. In a subset of subjects, cytokine levels and LTL were compared in survivors with DLCO above or below the mean using a Student t-test or Fisher’s Exact test, respectively. Results: Seventy-two HL survivors met inclusion criteria (mean age at diagnosis=14 years, range: 3-18 years). Mean off-therapy DLCO was 75% (range: 52-98%), below the lower limit of normal (76%) in healthy populations. DLCO was inversely associated with female sex (p = 0.002). Five of 24 survivors (21%) had LTL ≤10th percentile for age, but there was no difference in LTL relative to DLCO. Survivors with DLCO ≤75% had higher IL1α and IL1β levels (n = 30, p = 0.07). Conclusions: HL survivors had lower than expected DLCO, with females at highest risk for impaired pulmonary diffusion. Twice as many survivors as expected had LTL ≤10th percentile, and PF-related cytokine profiles were observed in survivors with lower DLCO, suggesting inflammation and telomere maintenance defects may contribute to late effects in HL survivors.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 572
Treatment outcome and prognostic factors in male patients with stage IV breast cancer: A population-based study.
572 Background: Stage IV male breast cancer (MBC) is a rare disease, previously described in small, single institutional studies. The purpose of this study is to investigate treatment outcome and prognostic factors in stage IV MBC. Methods: Patients with stage IV MBC diagnosed between 1988 and 2012 who did not receive radiation therapy as part of the first course of treatment were selected from the SEER database. Treatment outcome and prognostic factors for disease-specific survival (DSS) and overall survival (OS) were evaluated. Results: We identified 8292 MBC cases and included 394 patients with stage IV disease, who had the required treatment information. Median overall survival was 21 months. The 5-year DSS and OS for stage IV MBC patients were 38.3% and 21.1%, respectively. Of those with known progesterone receptor (PR) status, 68.6% were PR-positive (PR+), which was associated with better DSS (P = 0.003) and OS (P < 0.001). Of the 394 patients, 197 (50%) received surgery for the primary tumor and 197 (50%) did not. Those undergoing primary tumor surgery had longer median DSS than those who did not (36 months VS 21months; p < 0.001). Additional factors that correlated with prolonged DSS and OS were smaller tumor size (P = 0.005, P = 0.009) and younger age (P = 0.021, P = 0.001). Significant associations with race, year of diagnosis, ER status, HER2 status, use of radiation therapy to the primary tumor were not observed. In multivariate analysis, smaller tumor size (OR, 1.93; 95% CI, 1.2-3.104), PR+ positivity (OR, 1.665; 95%CI, 1.201-2.309), younger age (OR, 1.456; 95%CI, 1.053-2.014) and surgery for primary tumor (OR, 0.506; 95%CI, 0.368-0.695) were associated with longer DSS. Conclusions: Although stage IV MBC has poor DSS and OS, patients with PR-negative (PR-) disease, older age ( > 65 years), tumor size > 2cm or those did not undergo initial surgery for primary tumor had the worst prognosis. This is the largest study of stage IV MBC to date and these findings will help address some of the inconsistencies regarding this rare type of breast cancer.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 572
Treatment outcome and prognostic factors in male patients with stage IV breast cancer: A population-based study.
572 Background: Stage IV male breast cancer (MBC) is a rare disease, previously described in small, single institutional studies. The purpose of this study is to investigate treatment outcome and prognostic factors in stage IV MBC. Methods: Patients with stage IV MBC diagnosed between 1988 and 2012 who did not receive radiation therapy as part of the first course of treatment were selected from the SEER database. Treatment outcome and prognostic factors for disease-specific survival (DSS) and overall survival (OS) were evaluated. Results: We identified 8292 MBC cases and included 394 patients with stage IV disease, who had the required treatment information. Median overall survival was 21 months. The 5-year DSS and OS for stage IV MBC patients were 38.3% and 21.1%, respectively. Of those with known progesterone receptor (PR) status, 68.6% were PR-positive (PR+), which was associated with better DSS (P = 0.003) and OS (P < 0.001). Of the 394 patients, 197 (50%) received surgery for the primary tumor and 197 (50%) did not. Those undergoing primary tumor surgery had longer median DSS than those who did not (36 months VS 21months; p < 0.001). Additional factors that correlated with prolonged DSS and OS were smaller tumor size (P = 0.005, P = 0.009) and younger age (P = 0.021, P = 0.001). Significant associations with race, year of diagnosis, ER status, HER2 status, use of radiation therapy to the primary tumor were not observed. In multivariate analysis, smaller tumor size (OR, 1.93; 95% CI, 1.2-3.104), PR+ positivity (OR, 1.665; 95%CI, 1.201-2.309), younger age (OR, 1.456; 95%CI, 1.053-2.014) and surgery for primary tumor (OR, 0.506; 95%CI, 0.368-0.695) were associated with longer DSS. Conclusions: Although stage IV MBC has poor DSS and OS, patients with PR-negative (PR-) disease, older age ( > 65 years), tumor size > 2cm or those did not undergo initial surgery for primary tumor had the worst prognosis. This is the largest study of stage IV MBC to date and these findings will help address some of the inconsistencies regarding this rare type of breast cancer.
- Open Access
- 29 November 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 894
3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma
Two-dimensional high-dose-rate brachytherapy (2D-HDR-BT) is an effective method of dose escalation for local tumor control in early T-stage nasopharyngeal carcinoma (NPC). Treatment outcomes for 3D-image-guided high-dose-rate brachytherapy (3D-image-guided-HDR-BT) after external beam radiotherapy (ERT) have not been examined in early T-stage NPC patients. The current study was designed to evaluate whether addition of 3D-HDR-BT to ERT showed further improvement in treatment outcomes in patients with early T-stage NPC when compared to 2D-HDR-BT after ERT.
- 29 November 2014
- Published by Springer Nature in BMC Cancer
- Vol. 14 (1) , 894
Open Access3D-image-guided HDR-brachytherapy versus 2D HDR - brachytherapy after external beam radiotherapy for early T-stage nasopharyngeal carcinoma
Two-dimensional high-dose-rate brachytherapy (2D-HDR-BT) is an effective method of dose escalation for local tumor control in early T-stage nasopharyngeal carcinoma (NPC). Treatment outcomes for 3D-image-guided high-dose-rate brachytherapy (3D-image-guided-HDR-BT) after external beam radiotherapy (ERT) have not been examined in early T-stage NPC patients. The current study was designed to evaluate whether addition of 3D-HDR-BT to ERT showed further improvement in treatment outcomes in patients with early T-stage NPC when compared to 2D-HDR-BT after ERT.
- 31 October 2014
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 3 (4) , 339-346
Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for “radioresistant” renal cell carcinoma (RCC)
- 31 October 2014
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 3 (4) , 339-346
Stereotactic body radiotherapy (SBRT)/stereotactic ablative body radiotherapy (SABR) for “radioresistant” renal cell carcinoma (RCC)
- Open Access
- 5 July 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 165
3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma
Background: To evaluate the therapeutic benefit of 3D-image-guided high-dose-rate intracavitary brachytherapy (3D-image-guided HDR-BT) used as a salvage treatment of intensity modulated radiation therapy (IMRT) in patients with locally persistent nasopharyngeal carcinoma (NPC). Methods: Thirty-two patients with locally persistent NPC after full dose of IMRT were evaluated retrospectively. 3D-image-guided HDR-BT treatment plan was performed on a 3D treatment planning system (PLATO BPS 14.2). The median dose of 16 Gy was delivered to the 100% isodose line of the Gross Tumor Volume. Results: The whole procedure was well tolerated under local anesthesia. The actuarial 5-y local control rate for 3D-image-guided HDR-BT was 93.8%, patients with early-T stage at initial diagnosis had 100% local control rate. The 5-y actuarial progression-free survival and distant metastasis-free survival rate were 78.1%, 87.5%. One patient developed and died of lung metastases. The 5-y actuarial overall survival rate was 96.9%. Conclusions: Our results showed that 3D-image-guided HDR-BT would provide excellent local control as a salvage therapeutic modality to IMRT for patients with locally persistent disease at initial diagnosis of early-T stage NPC.
- 5 July 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 165
Open Access3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma
Background: To evaluate the therapeutic benefit of 3D-image-guided high-dose-rate intracavitary brachytherapy (3D-image-guided HDR-BT) used as a salvage treatment of intensity modulated radiation therapy (IMRT) in patients with locally persistent nasopharyngeal carcinoma (NPC). Methods: Thirty-two patients with locally persistent NPC after full dose of IMRT were evaluated retrospectively. 3D-image-guided HDR-BT treatment plan was performed on a 3D treatment planning system (PLATO BPS 14.2). The median dose of 16 Gy was delivered to the 100% isodose line of the Gross Tumor Volume. Results: The whole procedure was well tolerated under local anesthesia. The actuarial 5-y local control rate for 3D-image-guided HDR-BT was 93.8%, patients with early-T stage at initial diagnosis had 100% local control rate. The 5-y actuarial progression-free survival and distant metastasis-free survival rate were 78.1%, 87.5%. One patient developed and died of lung metastases. The 5-y actuarial overall survival rate was 96.9%. Conclusions: Our results showed that 3D-image-guided HDR-BT would provide excellent local control as a salvage therapeutic modality to IMRT for patients with locally persistent disease at initial diagnosis of early-T stage NPC.
- 5 May 2013
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 2 (2) , 209-216
Schedule-dependent interactions between perifosine and radiotherapy in prostate cancer
- 5 May 2013
- Published by Springer Nature in Journal of Radiation Oncology
- Vol. 2 (2) , 209-216
Schedule-dependent interactions between perifosine and radiotherapy in prostate cancer
- 9 April 2013
- Published by Wiley in International Journal of Urology
- Vol. 20 (12) , 1178-1183
Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: Clinical outcomes
Objectives: To evaluate biochemical non‐evidence of disease and adverse events of salvage intensity‐modulated radiotherapy using an endorectal balloon for prostate cancer patients after radical prostatectomy.Methods: Data of 107 patients (median age 65 years) with persistent (>0.1 ng/mL) or rising prostate‐specific antigen after radical prostatectomy were retrospectively analyzed. The mean dose to clinical target volume was 70 Gy in 32 fractions (the equivalent dose in 2 Gy fraction is 73.2 Gy based on α:β = 2). Biochemical non‐evidence of disease and predictive factors were assessed. Genitourinary toxicity and gastrointestinal toxicity were also evaluated using the Radiation Therapy Oncology Group toxicity criteria.Results: The median follow up was 37 months (range 6–126 months). A total of 48 patients developed biochemical recurrence. The 3‐ and 5‐year biochemical non‐evidence of disease rates of all patients were 52.6% and 48.8%, respectively. The Gleason score (≥4 + 3, ≤3 + 4) and pre‐intensity‐modulated radiotherapy prostate‐specific antigen level (≥0.5 ng/mL, <0.5 ng/mL) were significant predictive factors for biochemical non‐evidence of disease in univariate analysis. In multivariate analysis, only the Gleason score was detected as a significant variable. The highest late genitourinary toxicities were grade 2 in 13% and grade 3 in 6% of patients. The highest late gastrointestinal toxicities were grade 2 in 6% and grade 3 in 3% of patients.Conclusion: Despite a relatively high radiation dose, intensity‐modulated radiotherapy with an endorectal balloon can be delivered with acceptable toxicity and efficacy for patients developing biochemical recurrence after radical prostatectomy.
- 9 April 2013
- Published by Wiley in International Journal of Urology
- Vol. 20 (12) , 1178-1183
Salvage intensity modulated radiotherapy using endorectal balloon after radical prostatectomy: Clinical outcomes
Objectives: To evaluate biochemical non‐evidence of disease and adverse events of salvage intensity‐modulated radiotherapy using an endorectal balloon for prostate cancer patients after radical prostatectomy.Methods: Data of 107 patients (median age 65 years) with persistent (>0.1 ng/mL) or rising prostate‐specific antigen after radical prostatectomy were retrospectively analyzed. The mean dose to clinical target volume was 70 Gy in 32 fractions (the equivalent dose in 2 Gy fraction is 73.2 Gy based on α:β = 2). Biochemical non‐evidence of disease and predictive factors were assessed. Genitourinary toxicity and gastrointestinal toxicity were also evaluated using the Radiation Therapy Oncology Group toxicity criteria.Results: The median follow up was 37 months (range 6–126 months). A total of 48 patients developed biochemical recurrence. The 3‐ and 5‐year biochemical non‐evidence of disease rates of all patients were 52.6% and 48.8%, respectively. The Gleason score (≥4 + 3, ≤3 + 4) and pre‐intensity‐modulated radiotherapy prostate‐specific antigen level (≥0.5 ng/mL, <0.5 ng/mL) were significant predictive factors for biochemical non‐evidence of disease in univariate analysis. In multivariate analysis, only the Gleason score was detected as a significant variable. The highest late genitourinary toxicities were grade 2 in 13% and grade 3 in 6% of patients. The highest late gastrointestinal toxicities were grade 2 in 6% and grade 3 in 3% of patients.Conclusion: Despite a relatively high radiation dose, intensity‐modulated radiotherapy with an endorectal balloon can be delivered with acceptable toxicity and efficacy for patients developing biochemical recurrence after radical prostatectomy.
- 1 April 2013
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (4) , 481-487
Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer
The management of pancreatic cancer continues to be challenging. Despite surgical, genetic and molecular advances, its overall prognosis remains poor. Surgical resection is the only modality that offers a chance for a cure, with an overall survival rate of 10-20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation. Conventional radiotherapy, with or without chemotherapy, has been used to treat patients with advanced-stage pancreatic cancer, an approach with high rates of local recurrence. Stereotactic body radiation therapy, also known as stereotactic ablative radiotherapy has emerged as a treatment modality that allows the precise delivery of a large ablative radiation dose to a tumor volume while sparing surrounding organs and tissues. Phase I and II studies have shown good rates of local control of the disease but rates of distant metastasis remain significant. Strategies to combine novel systemic therapy and stereotactic body radiation therapy are to be explored.
- 1 April 2013
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 13 (4) , 481-487
Emerging role of stereotactic body radiotherapy in the treatment of pancreatic cancer
The management of pancreatic cancer continues to be challenging. Despite surgical, genetic and molecular advances, its overall prognosis remains poor. Surgical resection is the only modality that offers a chance for a cure, with an overall survival rate of 10-20% at 5 years. However, only 20% of the patients are surgical candidates because of locally advanced disease or systemic stage at presentation. Conventional radiotherapy, with or without chemotherapy, has been used to treat patients with advanced-stage pancreatic cancer, an approach with high rates of local recurrence. Stereotactic body radiation therapy, also known as stereotactic ablative radiotherapy has emerged as a treatment modality that allows the precise delivery of a large ablative radiation dose to a tumor volume while sparing surrounding organs and tissues. Phase I and II studies have shown good rates of local control of the disease but rates of distant metastasis remain significant. Strategies to combine novel systemic therapy and stereotactic body radiation therapy are to be explored.
- 1 January 2013
- Published by Springer Nature
- p. E3
Erratum: Bone Metastasis
- 1 October 2012
- Published by Elsevier in Practical Radiation Oncology
- Vol. 2 (4) , 270-273
Preservation of adrenal function after successful stereotactic body radiation therapy of metastatic renal cell carcinoma involving the remaining contralateral adrenal gland
- 1 October 2012
- Published by Elsevier in Practical Radiation Oncology
- Vol. 2 (4) , 270-273
Preservation of adrenal function after successful stereotactic body radiation therapy of metastatic renal cell carcinoma involving the remaining contralateral adrenal gland